RX 0301
Alternative Names: HC-0301; RX-0301; WGI-0301Latest Information Update: 14 Jun 2024
At a glance
- Originator Rexahn Pharmaceuticals
- Developer Rexahn Pharmaceuticals; Zhejiang Haichang Biotechnology
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Liver cancer
- Discontinued Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
Most Recent Events
- 05 Apr 2024 Preclinical trials in Liver cancer in China (unspecified route) prior to April 2024
- 05 Apr 2024 Pharmacodynamics and adverse events data from preclinical studies in Liver cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical studies in Liver cancer were presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)